SOSV

InnSight Technology is a biotechnology company focused on enhancing diagnostics and evaluation of eye diseases. The company develops innovative ophthalmic devices, including a novel hand-held biosensor designed for the detection of anterior ophthalmic injuries. Additionally, InnSight Technology works on advanced nanotechnology-based medical devices aimed at addressing specific clinical needs in ophthalmology. By providing these tools, the company seeks to improve ocular care for clinicians and their patients.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

GlowDx is a diagnostics company based in Midleton, Ireland, established in 2015. The company focuses on decentralizing molecular testing through innovative point-of-care technologies, which facilitate local access to diagnostics for tropical diseases. By combining novel molecular technology with effective delivery models, GlowDx aims to improve clinical outcomes while reducing the economic burden on patients and healthcare systems. This approach enhances the quality of life for individuals by ensuring they receive timely and accurate diagnostic information, thereby enabling healthcare providers to offer better-targeted treatments.

EIO Diagnostics Inc. is a Canadian company specializing in mastitis detection systems for dairy cattle. Founded in 2017 and based in Duncan, the company has developed the FirstLook Mastitis system, which employs a multispectral sensor to capture images of the udder as cows enter the milk parlor. This technology utilizes infrared image analysis and computer vision to automate the detection of early indicators of mastitis, allowing farmers to prevent infections before they occur. By installing a single sensor at the entry of the rotary milking system, EIO Diagnostics enables farmers to monitor udder health efficiently, thereby enhancing livestock health and improving milk quality while reducing labor and associated costs.

FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

Lief Therapeutics is a medical device company focused on improving at-home care for individuals suffering from post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet biosensing patch that measures heart rate and breathing patterns with medical accuracy. This wearable device, known as Lief, helps users manage their stress responses through biofeedback exercises, allowing them to monitor their emotions and behaviors in real-time. Additionally, the device provides clinicians with insights into patient progress, enabling in-session training and tracking of psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, facilitating the tracking of daily progress and personalized practice exercises. Founded in 2014 and based in San Francisco, California, the company sells its products online.

Flowbio is a wellness and fitness services company that specializes in hydration monitoring for athletes, including triathletes, cyclists, and runners. The firm has developed a real-time hydration biosensor platform that utilizes a wearable, non-invasive patch to analyze sweat and assess key biomarkers, focusing initially on electrolytes and total body fluid loss. This technology enables users to receive personalized recommendations to enhance their athletic performance by better managing their hydration levels.

Level Zero Health is a technology company specializing in advanced biosensor solutions. It develops wearable devices equipped with DNA-based sensors, designed to precisely monitor key endocrine biomarkers in real-time. By combining biochemistry and nanotechnology, the company collects novel data, empowering users to gain insights into their hormonal health.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

LightHearted AI specializes in AI-driven remote cardiovascular diagnostics, offering a tool for swift, accurate, and cost-effective detection of heart conditions. Their medical device aims to prevent heart-related deaths by providing healthcare professionals with faster, more precise, and affordable support than existing technologies, thereby enhancing treatment procedures.

MedIQ is an integrated virtual care platform providing on-demand healthcare at the point of need. MedIQ redefines healthcare through a digitally enabled, cashless, hybrid healthcare ecosystem. MedIQ makes high-quality, modernized healthcare and wellness available to everyone.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Care Constitution is a telehealth service that provides a platform for clients to access health checkups online. The company focuses on improving healthcare delivery by assisting doctors with diagnostic testing through the use of artificial intelligence technology. This innovative approach aims to set a standard of care in medicine by offering objective, reproducible, and quantitative healthcare assessments. By enhancing the accuracy of diagnoses, Care Constitution seeks to support healthcare professionals in delivering better patient outcomes.

OpenShelf, founded in 2023, develops an inventory automation system aimed at optimizing contact lens management for optometrists. The company offers flexible robotic solutions that can handle, sort, and dispense thousands of unique contact lens boxes. This technology allows optometrists to gain valuable insights into their inventory, such as when to reorder specific prescriptions and the frequency of stock replenishment at their practice. By streamlining the contact lens inventory process, OpenShelf enhances operational efficiency and supports better patient care.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Dia has invented an electrochemical sensor that can measure a wide variety of chemical biomarkers non-invasively in saliva or sweat. The data is sent via Bluetooth to an app on the user’s smartphone and analyzed in real-time. From the app, it can be securely sent to a third party. To date, we have measured hormones, electrolytes, neurotransmitters and metabolites. At DIA, we let the biology dictate which analyte we put on which platform – our wearable arm sleeve for sweat or our table-top device for saliva – because some biomarkers, such as cortisol fluctuate throughout the day and need to be monitored through a wearable sensor, while others, such as creatinine are more suitable to a daily saliva test.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Lief Therapeutics is a medical device company focused on improving at-home care for individuals suffering from post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet biosensing patch that measures heart rate and breathing patterns with medical accuracy. This wearable device, known as Lief, helps users manage their stress responses through biofeedback exercises, allowing them to monitor their emotions and behaviors in real-time. Additionally, the device provides clinicians with insights into patient progress, enabling in-session training and tracking of psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, facilitating the tracking of daily progress and personalized practice exercises. Founded in 2014 and based in San Francisco, California, the company sells its products online.

Metabolomic Diagnostics Ltd., established in 2011 and based in Little Island, Ireland, is a medical diagnostics company focused on early disease detection. It specializes in developing a mass spectrometry-based diagnostic platform that analyzes multiple biomarkers simultaneously, enabling predictive diagnosis of complex diseases. The company's primary application is a blood test for predicting the risk of pre-eclampsia, a pregnancy complication characterized by high blood pressure and protein in the urine, which can lead to restricted blood supply to the fetus. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve pregnancy outcomes through early intervention.

Sava is a company focused on advancing biosensing technology to enhance personal health monitoring. By providing real-time feedback on the body's molecular signature, particularly for athletes, Sava's technology allows for continuous and effortless monitoring of crucial metrics such as glucose and lactate levels. This capability enables athletes to train more effectively, predict fatigue, and optimize their dietary plans. Sava's innovative approach aims to make health information more accessible, delivering insights in a painless and affordable manner, thereby redefining how individuals interact with their health.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Untap Health has developed a pathogen monitoring platform focused on enhancing community health by detecting infections before they escalate into outbreaks. The platform analyzes wastewater samples from various sources, including commercial sites, schools, and wastewater treatment facilities, to identify viruses present in sewage. By leveraging high-frequency data, Untap provides early warnings of potential health incidents, facilitating timely interventions. This non-invasive and anonymized approach enables communities to maintain cleanliness and safety, effectively contributing to public health monitoring and management.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

ChektAhora specializes in providing at-home testing kits for sexually transmitted infections (STIs) and other contagious diseases, including respiratory viruses like influenza and COVID-19. The company offers a technology-enabled platform that allows customers to access confidential and convenient health tests without the discomfort of traditional testing methods. By utilizing advanced testing techniques such as PCR, antigens, and antibodies, ChektAhora aims to deliver laboratory-quality results directly to individuals in Latin America, ensuring a pain-free experience.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

ChronosDx is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics. The firm focuses on creating bioassay technology tailored for diagnostics, drug screening, and development. ChronosDx develops high-performance, cost-effective, and scalable technology that effectively detects various biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This innovative platform enables medical professionals to monitor biomarkers both in-line and in vivo, enhancing the capabilities of healthcare diagnostics.

GlowDx is a diagnostics company based in Midleton, Ireland, established in 2015. The company focuses on decentralizing molecular testing through innovative point-of-care technologies, which facilitate local access to diagnostics for tropical diseases. By combining novel molecular technology with effective delivery models, GlowDx aims to improve clinical outcomes while reducing the economic burden on patients and healthcare systems. This approach enhances the quality of life for individuals by ensuring they receive timely and accurate diagnostic information, thereby enabling healthcare providers to offer better-targeted treatments.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Paragon Pure is a food company focused on developing natural ingredients that cater to contemporary dietary needs. The firm specializes in producing a healthy and sustainable structured fat and flavor system derived from upcycled rice bran, particularly for use in alternative proteins. By leveraging expertise in flavor encapsulation, process engineering, and physical chemistry, Paragon Pure aims to create genuine ingredients that deliver natural flavors, colors, and nutrients in wholesome foods. This approach enables consumers to fully enjoy the diverse flavors of various spices while adhering to healthier eating practices.

EIO Diagnostics Inc. is a Canadian company specializing in mastitis detection systems for dairy cattle. Founded in 2017 and based in Duncan, the company has developed the FirstLook Mastitis system, which employs a multispectral sensor to capture images of the udder as cows enter the milk parlor. This technology utilizes infrared image analysis and computer vision to automate the detection of early indicators of mastitis, allowing farmers to prevent infections before they occur. By installing a single sensor at the entry of the rotary milking system, EIO Diagnostics enables farmers to monitor udder health efficiently, thereby enhancing livestock health and improving milk quality while reducing labor and associated costs.

Kinexcs is an AI-driven health platform and wearables company focused on enhancing mobility and improving quality of life for individuals with musculoskeletal conditions. It addresses issues of incomplete recovery and patient compliance through its innovative digital therapy solutions, which are both cost-effective and convenient. The company has developed KIMIA, the world's first continuous knee health monitor, combined with an AI-based digital therapist that facilitates access to therapy. Kinexcs collaborates with key opinion leaders and major public hospitals in Singapore on various clinical projects, while also offering its products through orthopedic surgeons and significant implant manufacturers. The integration of continuous monitoring and real-time exercise guidance supports patients in managing their conditions effectively.

PONS is a company specializing in the development of artificial intelligence to enhance ultrasound imaging, particularly for brain diagnostics. Utilizing machine learning algorithms, PONS transforms traditional ultrasound systems into smart, AI-driven diagnostic tools that improve scan resolution, tissue contrast, and noise reduction. This innovation aims to provide expert-level insights without the need for costly new hardware. The company's primary objective is to create a wearable ultrasound device to assist first responders and ambulance doctors with pre-diagnostics in challenging circumstances, facilitating early disease detection and preventive screening. By focusing on important anatomical features in ultrasound scans, PONS seeks to advance the capabilities of ultrasound technology in neurosurgery and related fields.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Flowbio is a wellness and fitness services company that specializes in hydration monitoring for athletes, including triathletes, cyclists, and runners. The firm has developed a real-time hydration biosensor platform that utilizes a wearable, non-invasive patch to analyze sweat and assess key biomarkers, focusing initially on electrolytes and total body fluid loss. This technology enables users to receive personalized recommendations to enhance their athletic performance by better managing their hydration levels.

Aksense is a biotechnology company focused on developing affordable and portable nucleic acid-based diagnostic panels for the rapid and accurate detection of pathogens. The company has created a portable rapid infection diagnostic biosensor designed to enhance healthcare by providing high-quality and safe care. Aksense's technology aims to improve antibiotic prescribing practices and public health outcomes by enabling early detection and treatment of infections. This approach reduces the spread of infections and improves patient outcomes, allowing users to achieve faster recovery through cost-effective molecular testing solutions.

Portable Diagnostic Systems is focused on developing a microfluidics-based drug testing platform tailored for law enforcement applications. Founded in August 2019, the company aims to enhance roadside drug screening by providing accurate results from a small saliva sample. This innovative approach employs salivary diagnostics and antibody engineering, allowing for quick and easy collection during traffic stops. The platform is designed to minimize false positives and meet the specific needs of police departments, thereby improving the reliability of drug testing in impaired driving cases.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

Metabolomic Diagnostics Ltd., established in 2011 and based in Little Island, Ireland, is a medical diagnostics company focused on early disease detection. It specializes in developing a mass spectrometry-based diagnostic platform that analyzes multiple biomarkers simultaneously, enabling predictive diagnosis of complex diseases. The company's primary application is a blood test for predicting the risk of pre-eclampsia, a pregnancy complication characterized by high blood pressure and protein in the urine, which can lead to restricted blood supply to the fetus. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve pregnancy outcomes through early intervention.

Zennea Technologies is a medical device company based in Surrey, Canada, specializing in the development of therapeutic wearables aimed at reducing snoring and improving overall health through enhanced sleep quality. The company's flagship product, ZENS, is a comfortable and discreet wearable designed to address chronic snoring and mild obstructive sleep apnea at its source. Zennea conducts clinical trials to validate the effectiveness of its technology, which not only targets snoring but also tracks sleep quality, assisting users in making informed decisions to enhance their sleep health.

PhableCare creates an ecosystem of patients, doctors, hospitals, health devices, insurance, and patient care service providers. In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring.

FoodMarble is a company that addresses the challenges faced by nearly one billion individuals with disruptive digestive symptoms. Its flagship product, AIRE, is a personal breath analyzer designed to help users identify which foods are best suited to their unique digestive systems. By utilizing a handheld device and a companion application, AIRE allows individuals to monitor their digestion in real time, leveraging techniques commonly employed in gastroenterology. This innovative approach empowers users to develop personalized diets that can alleviate discomfort and improve their overall well-being. Since its inception, FoodMarble has garnered significant interest, receiving over $500,000 in pre-orders prior to the commencement of device shipments in late 2017. The company aims to create the first comprehensive dataset of its kind, further enhancing users' ability to manage their digestive health.

Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Harae Dx Corp. is a medical diagnostics company specializing in cancer detection. The company has created an automated, portable system that facilitates early cancer diagnosis by identifying cancer biomarkers directly, eliminating the need to send samples to third-party laboratories. This innovative approach reduces the risk of human error in processing and enhances the speed of results, allowing healthcare professionals to detect and treat cancer more effectively and affordably. Harae Dx's compact and cost-efficient solution aims to improve patient outcomes through timely and accurate diagnostics.

FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

PONS is a company specializing in the development of artificial intelligence to enhance ultrasound imaging, particularly for brain diagnostics. Utilizing machine learning algorithms, PONS transforms traditional ultrasound systems into smart, AI-driven diagnostic tools that improve scan resolution, tissue contrast, and noise reduction. This innovation aims to provide expert-level insights without the need for costly new hardware. The company's primary objective is to create a wearable ultrasound device to assist first responders and ambulance doctors with pre-diagnostics in challenging circumstances, facilitating early disease detection and preventive screening. By focusing on important anatomical features in ultrasound scans, PONS seeks to advance the capabilities of ultrasound technology in neurosurgery and related fields.

LOOX is a London-based mobile application that facilitates on-demand appointment bookings with beauty, health, and fitness professionals. Launched in 2014, the platform connects users with local service providers, streamlining the booking process and enhancing convenience.

Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Hydrostasis is a company based in San Diego, California, that specializes in developing hydration monitoring systems tailored for athletes. Its technology includes wearable sensors that assess individual hydration needs based on body composition, providing personalized and clinical-grade accuracy. The system offers real-time notifications to alert athletes before dehydration affects their performance. In addition to serving athletes, Hydrostasis collaborates with device manufacturers for both consumer and clinical applications, enhancing hydration monitoring capabilities across various platforms. By leveraging scientific methodologies and cloud-based data storage, Hydrostasis aims to empower athletes to optimize their hydration levels, ultimately supporting their physical and mental performance.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

LOOX is a London-based mobile application that facilitates on-demand appointment bookings with beauty, health, and fitness professionals. Launched in 2014, the platform connects users with local service providers, streamlining the booking process and enhancing convenience.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device designed for blood type analysis and the detection of infectious diseases. The company's flagship product offers rapid and accurate testing for various conditions, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. This portable device operates independently of electricity or laboratory infrastructure, making it accessible for use in diverse environments. Additionally, Criam's technology is scalable, allowing a single reader to perform multiple tests using specific cartridges and advanced computer vision algorithms. By optimizing blood testing services, Criam aims to provide timely health information and improve clinical decision-making.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Paragon Pure is a food company focused on developing natural ingredients that cater to contemporary dietary needs. The firm specializes in producing a healthy and sustainable structured fat and flavor system derived from upcycled rice bran, particularly for use in alternative proteins. By leveraging expertise in flavor encapsulation, process engineering, and physical chemistry, Paragon Pure aims to create genuine ingredients that deliver natural flavors, colors, and nutrients in wholesome foods. This approach enables consumers to fully enjoy the diverse flavors of various spices while adhering to healthier eating practices.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

Untap Health has developed a pathogen monitoring platform focused on enhancing community health by detecting infections before they escalate into outbreaks. The platform analyzes wastewater samples from various sources, including commercial sites, schools, and wastewater treatment facilities, to identify viruses present in sewage. By leveraging high-frequency data, Untap provides early warnings of potential health incidents, facilitating timely interventions. This non-invasive and anonymized approach enables communities to maintain cleanliness and safety, effectively contributing to public health monitoring and management.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

EIO Diagnostics Inc. is a Canadian company specializing in mastitis detection systems for dairy cattle. Founded in 2017 and based in Duncan, the company has developed the FirstLook Mastitis system, which employs a multispectral sensor to capture images of the udder as cows enter the milk parlor. This technology utilizes infrared image analysis and computer vision to automate the detection of early indicators of mastitis, allowing farmers to prevent infections before they occur. By installing a single sensor at the entry of the rotary milking system, EIO Diagnostics enables farmers to monitor udder health efficiently, thereby enhancing livestock health and improving milk quality while reducing labor and associated costs.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Neurode is focused on the development of a non-invasive wearable headset aimed at enhancing cognitive performance for individuals with neurological conditions, particularly ADHD. This innovative device employs electrical stimulation to address the imbalances in brain activity commonly associated with ADHD. Alongside the headset, Neurode offers a companion application that monitors users' progress and shares improvements with healthcare professionals. This drug-free approach seeks to alleviate symptoms such as working memory deficits, attention challenges, and impulse control issues, ultimately enabling better management of cognitive performance for users.

Sava is a company focused on advancing biosensing technology to enhance personal health monitoring. By providing real-time feedback on the body's molecular signature, particularly for athletes, Sava's technology allows for continuous and effortless monitoring of crucial metrics such as glucose and lactate levels. This capability enables athletes to train more effectively, predict fatigue, and optimize their dietary plans. Sava's innovative approach aims to make health information more accessible, delivering insights in a painless and affordable manner, thereby redefining how individuals interact with their health.

XXICO is a platform consisting of devices and software that enable remote health monitoring.

Harae Dx Corp. is a medical diagnostics company specializing in cancer detection. The company has created an automated, portable system that facilitates early cancer diagnosis by identifying cancer biomarkers directly, eliminating the need to send samples to third-party laboratories. This innovative approach reduces the risk of human error in processing and enhances the speed of results, allowing healthcare professionals to detect and treat cancer more effectively and affordably. Harae Dx's compact and cost-efficient solution aims to improve patient outcomes through timely and accurate diagnostics.

Neurocess specializes in wearable technology designed to enhance training performance and minimize injury risks for professional athletes. The company develops attachable sensors that monitor muscle activity during training sessions. These sensors capture critical data on muscle balance, contraction rates, fatigue levels, injury risks, and dehydration. By providing this valuable information, Neurocess enables coaches and athletes to optimize training efficiency and implement preventative measures against injuries.

Kite Medical, established in 2016 and headquartered in Galway, Ireland, specializes in the manufacture of a non-invasive, wearable device for detecting kidney reflux in children with urinary tract infections. This innovative technology aims to replace complex procedures and hospital visits, improving the patient experience and clinical outcomes. Kidney reflux, the most common urological disorder in childhood, affects up to three percent of young children, predominantly between six months and five years of age. Early detection is crucial to prevent potential kidney damage and failure.

Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

PhableCare creates an ecosystem of patients, doctors, hospitals, health devices, insurance, and patient care service providers. In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Flowbio is a wellness and fitness services company that specializes in hydration monitoring for athletes, including triathletes, cyclists, and runners. The firm has developed a real-time hydration biosensor platform that utilizes a wearable, non-invasive patch to analyze sweat and assess key biomarkers, focusing initially on electrolytes and total body fluid loss. This technology enables users to receive personalized recommendations to enhance their athletic performance by better managing their hydration levels.

FoodMarble is a company that addresses the challenges faced by nearly one billion individuals with disruptive digestive symptoms. Its flagship product, AIRE, is a personal breath analyzer designed to help users identify which foods are best suited to their unique digestive systems. By utilizing a handheld device and a companion application, AIRE allows individuals to monitor their digestion in real time, leveraging techniques commonly employed in gastroenterology. This innovative approach empowers users to develop personalized diets that can alleviate discomfort and improve their overall well-being. Since its inception, FoodMarble has garnered significant interest, receiving over $500,000 in pre-orders prior to the commencement of device shipments in late 2017. The company aims to create the first comprehensive dataset of its kind, further enhancing users' ability to manage their digestive health.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Magellan Life Sciences Ltd. is a synthetic biology company based in London, United Kingdom, specializing in the development of plant-based proteins for the food and beverage industries. Established in 2018, the company focuses on creating innovative protein sweeteners, including brazzein, utilizing its proprietary protein engineering and expression platforms. These novel protein-based molecules are designed to offer non-calorific alternatives that address sugar content and associated health concerns. By providing advanced solutions for the food, health, and nutrition sectors, Magellan Life Sciences aims to meet the growing demand for healthier ingredients in consumer products.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

FoodMarble is a company that addresses the challenges faced by nearly one billion individuals with disruptive digestive symptoms. Its flagship product, AIRE, is a personal breath analyzer designed to help users identify which foods are best suited to their unique digestive systems. By utilizing a handheld device and a companion application, AIRE allows individuals to monitor their digestion in real time, leveraging techniques commonly employed in gastroenterology. This innovative approach empowers users to develop personalized diets that can alleviate discomfort and improve their overall well-being. Since its inception, FoodMarble has garnered significant interest, receiving over $500,000 in pre-orders prior to the commencement of device shipments in late 2017. The company aims to create the first comprehensive dataset of its kind, further enhancing users' ability to manage their digestive health.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Mobio Interactive Inc. specializes in creating digital tools that enhance mental health and well-being for both consumers and clinical populations. Founded in 2014 and headquartered in Toronto, Canada, with additional offices in Zurich, Switzerland, and Shanghai, China, the company has developed applications such as Am Mindfulness, Wildflowers Mindfulness, and Actify Mindfulness. These applications provide medical-grade mindfulness training while objectively measuring the effectiveness of mindfulness practices through advanced analytics. Mobio's AI-powered digital theragnostic platform delivers clinically validated psychotherapy programs tailored to individual patients, utilizing digital biomarkers to assess human brain states without the need for wearable devices. The platform ensures secure and private interactions for users, allowing them to engage with mental health resources from anywhere in the world.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.